The United States will likely fail to meet President Joe Biden’s goal to deliver at least one Covid-19 vaccine to 70 percent of adults by July 4, officials said on June 22 and warned the Delta variant first found in India poses the greatest threat to U.S. eradication efforts.
Younger adults are seeking out Covid-19 vaccines at a slower rate than older adults, and if that pace of vaccination continues through August, vaccine coverage among younger adults will not reach levels achieved with older adults, U.S. Centers for Disease Control and Prevention (CDC) reported on June 21.
Coronavirus-related deaths worldwide passed a grim milestone of 4 million on June 17, according to a Reuters tally, as many countries struggle to procure enough vaccines to inoculate their populations.
Fully vaccinated visitors to Walt Disney Co.’s U.S. theme parks will not be required to wear face masks in most areas starting on June 15, the company said, as the country’s Covid-19 cases continue to decline.
Novavax Inc.’s experimental Covid-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.
The summit of the Group of Seven industrialized nations in southwest England saw global leaders pledging at least 1 billion Covid-19 vaccines for underdeveloped countries and struggling nations.
The United States will continue to press for a waiver of intellectual property rights for Covid-19 vaccines and treatments even as it and other Group of Seven rich nations sharply expand donations of vaccines to poorer countries.
The U.S. Centers for Disease Control and Prevention (CDC) eased travel recommendations for more than 110 countries and territories, including Japan just ahead of the Olympics.
From free beer to free childcare, President Joe Biden on June 2 touted new efforts to get 70 percent of U.S. adults at least one shot of vaccination against Covid-19 by the July 4 Independence Day holiday.
An inhalation version of CanSino Biologics’ Covid-19 vaccine is being tested in a Phase II clinical trial, Chief Executive Yu Xuefeng said on June 2.